New AusVaxSafety research which analysed 392,268 survey responses via AusVaxSafety’s national active safety surveillance system between July 2021 and May 2022, has found that Australian children aged 5-15 years report fewer side effects in the days following mRNA COVID-19 vaccination than those reported in clinical trials and published safety data.
Importantly, fever was reported low in the youngest age group, comparable to that seen following annual influenza vaccination. Additionally, there were also no self-reported cases of myocarditis and pericarditis identified in the study.
AusVaxSafety will commence surveillance in children aged 6 months to 5 years once COVID-19 vaccines become available in this age group.
To access the research in full, click on the link below.
Safety of COVID-19 vaccines in >200,000 Aussie kids: reassuring data from AusVax安全